Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability. Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. Nov. 07, 2025 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera”

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children Impetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric offices Private convertible notes financing will s

Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic approach is designed to enable in vivo expansion and activation of infused T cell receptor engineered T cells (TCR-Ts) to provide durability, tolerability and enhanced clinical benefit while reducing manufacturing complexity Compelling data generated in preclinical models of multiple solid tumors, inclu

4 November 2025 – On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera)1. Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior by Metsera’s board of directors. The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity to ma

Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure Nov. 03, 2025 -- InterCure Ltd. (Nasdaq: INCR / TASE: INCR) (“InterCure” or the “Company”) today announced it has entered into a defin

Oct. 31, 2025 -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) specializing in ADCs and complex biologics, today announced a strategic collaboration to advance ADC development and manufacturing. Through this collaboration, IntoCell’s proprietary OHPAS drug-linker platform, which includes Duocarmy

Oct. 31, 2025 -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, and Globalink Investment Inc., a Delaware corporation and a special purpose acquisition company (“Globalink”), today jointly announced the successful completion (“Closing”) of their previously announced business combination (“Business Combin

Oct. 30, 2025 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an investigational antisense oligonucleotide (ASO) for Angelman syndrome (AS). Data from the Aurora study will expand the population of Angelman patients treated to include both younger and older patients and those with other non-deletion AS genotypes not included in the Phase 3 Aspire

Oct. 30, 2025 -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity funding round. DefEYE was esta

October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration further expands Swarm’s